Xenon Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: XENEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
36.44+0.28 (+0.77%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xenon Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Xenon Pharmaceuticals generated -$95.4 million of operating cash flow and spent $275,000 on capital expenditures. That left free cash flow of -$95.7 million.
Summary generated from market data by MetaCap's automated system. Methodology
Xenon Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -110.74M | -102.30M | -105.26M | -90.90M | -84.71M | -65.05M | -65.69M | -62.79M | -57.92M | -47.93M | -44.74M | -48.46M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 558.00K | 587.00K | 611.00K | 641.00K | 632.00K | 659.00K | 666.00K | 667.00K | 641.00K | 586.00K | -629.00K | 1.73M |
| Stock-Based Compensation | 16.73M | 16.89M | 14.12M | 13.71M | 13.71M | 12.17M | 13.60M | 13.00M | 14.72M | 9.40M | 9.18M | 8.74M |
| Change in Working Capital | 3.26M | -3.24M | 9.86M | 5.02M | -4.62M | -11.89M | 3.41M | -911.00K | 10.09M | -5.65M | -522.00K | -3.30M |
| Operating Cash Flow | -95.39M | -88.90M | -81.48M | -71.75M | -64.23M | -61.65M | -54.38M | -49.66M | -31.15M | -46.19M | -35.40M | -48.08M |
| Capital Expenditures | -275.00K | -133.00K | -318.00K | -281.00K | -157.00K | -43.00K | -783.00K | -590.00K | -1.51M | -188.00K | -78.00K | -1.20M |
| Investing Cash Flow | -331.24M | -407.28M | 62.70M | 38.53M | 82.26M | 34.51M | 98.50M | 498.00K | 109.19M | -43.19M | -239.79M | 53.88M |
| Financing Cash Flow | 26.00K | 843.01M | 113.54M | 2.36M | 65.00K | 1.15M | 12.13M | 0 | 0 | 0 | 324.01M | — |
| Net Change in Cash | -426.34M | 346.70M | 94.65M | -30.87M | 18.72M | -26.05M | 55.09M | -49.11M | 77.84M | -89.75M | 49.07M | 35.02M |
| Free Cash Flow | -95.67M | -89.03M | -81.80M | -72.03M | -64.39M | -61.70M | -55.17M | -50.26M | -32.67M | -46.38M | -35.48M | -49.28M |
This table shows 12 quarterly periods of Xenon Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow XENE's reporting calendar. What is a cash flow statement?